Late last month, the FDA finalized a new guidance document, explaining the agency's current thinking on the circumstances that may arise in connection with an establishment inspection that it would consider to impose an inappropriate limitation on its inspection authority. The Food and Drug Administration Safety and Innovation Act (FDASIA) deems a drug or medical device adulterated if it has been manufactured processed, packed, or held in any factory, warehouse, or establishment that delays, denies, or limits an inspection, or refuses to permit entry or inspection.
The ...
Written by Guest Bloggers: Amanda R. Strainis-Walker and Eric J. Conn
Below is a set of important questions that we are frequently asked by clients when OSHA unexpectedly shows up at their doorsteps. These questions and many more are also addressed in our OSHA Inspection Checklist desk reference guide.
Scenario 1: An OSHA Compliance Safety and Health Officer (CSHO) arrives unannounced to begin an inspection, but the employer’s representative whom the employer desires to manage the OSHA inspection is not present at the workplace. Can the employer request that the CSHO return later ...
Blog Editors
Recent Updates
- OCR Withdraws Appeal of District Court Order Declaring Unlawful and Vacating the “Proscribed Combination” Portion of Its HIPAA Online Tracking Technologies Guidance
- As the Window for Comments Closes on ONC/ASTP’s HTI-2 Proposed Rule: What’s in HTI-2 and What Does It Mean for You?
- Unpacking Averages: Assessing FDA’s Postmarket Surveillance Under Section 522
- Video: New State Legislation Increases Oversight of Health Care Transactions – Thought Leaders in Health Law
- Video: New HIPAA Final Rule - Key Changes to Reproductive Health Care Privacy – Thought Leaders in Health Law